Overall, dysregulated cytokine signaling, particularly involving TGF-β and IL-33, along with NO-mediated oxidative stress, contribute significantly to the pathogenesis of IBD, highlighting potential therapeutic targets for intervention (221, 222) (Figure 9). Here, TGFB1 is linked to inflammatory bowel disease.